© 2026 Sinochem Nanjing Corporation,
All Right Reserved
My early days in pharmaceutical chemistry taught me to value the journey behind every molecule on a medicine shelf. It’s easy to look past intermediates like Posaconazole Intermediate 2, but their evolution tracks the growth of antifungal therapy. The search for next-level triazole antifungals started in the late 1990s out of necessity; invasive fungal infections began outpacing older treatments, pressing researchers for better options. Teams pushing for Posaconazole understood that robust intermediates would shape the future of safer, more potent drugs. The methods developed back then to synthesize and purify these crucial intermediates now lay the groundwork for scalable manufacturing worldwide, especially as fungal disease continues to strain health systems, particularly among immunocompromised patients.
Posaconazole Intermediate 2 serves as a core building block for the final antifungal molecule. Several years ago, I watched colleagues in chemical development argue over tweaks in precursor structures, knowing small changes would alter the profile of the finished active pharmaceutical ingredient. This intermediate holds distinct importance: it introduces specific side chains essential to bind fungal enzymes tightly, thus boosting the drug’s antifungal punch and spectrum.
Anyone working in chemical production knows the challenges of handling crystalline intermediates. This intermediate appears as a white, sometimes off-white solid, typically forming needle-like crystals. Melting points often hit the high 70s to low 80s Celsius—a useful indicator during purity checks. Its molecular weight and unique halogen substitutions give it specific solubility characteristics, making it easier or tougher to work with based on your solvent system. A strong odor sometimes emerges, a reminder to check ventilation wherever synthesis and isolation happen.
Clear labeling goes beyond legal compliance. My days in QA hammered home the point: one slip here leads to batch confusion or worse, safety violations. Labels on this intermediate flag batch number, purity (usually at least 98%), storage conditions (cool, dry space essential), and expiration date. Specifications get exacting—GC or HPLC chromatograms display typical impurity profiles, while moisture content hides nowhere thanks to Karl Fischer titration. These standards lower risks for downstream reactions, keeping the end product consistent and safe.
Crafting this intermediate takes a series of well-choreographed chemical steps. Early on, process chemists puzzled through optimizing key couplings to avoid expensive reagents and minimize toxic byproducts. I've seen the focus shift from batch-wise, glassware-scale reactions to more efficient flow chemistry setups. In general, the pathway involves selective halogenation, careful functional group protection, and judicious hydrolysis. Each step demands vigilance over reaction times, catalysts, and precise temperature control. Those in pilot plant runs know that small leaks or hot spots can ruin an entire lot, so operator skill often makes the difference between success and costly waste.
The beauty of organic chemistry shows when tweaking intermediates like this to adjust properties downstream. I remember a project where a single methyl group swap in a side chain yielded a more stable final API version. Here, chemical reactions include cyclization, nucleophilic substitution, and controlled oxidation. Each transformation must avoid unwanted rearrangements that might introduce impurities challenging to remove at scale. Protecting groups get attached and trimmed away with care, using reagents selected as much for safety and environmental impact as for efficiency.
The scientific world loves aliases nearly as much as the world of espionage. In documentation, Posaconazole Intermediate 2 turns up under several labels: "Intermediate B", "tert-Butyl-[(2R,3S)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-[4-(4-fluorophenyl)piperidin-1-yl]propan-2-yl]carbamate", or proprietary code numbers from contract manufacturers. This constant juggling of names across regulatory filings, supplier records, and internal systems adds stress come audit season, so cross-checking and harmonizing records matters for anyone managing production or FDA inspections.
Worker protection lands front and center with intermediates bearing fluorines or triazole rings. At scale, the dust from crystalline intermediates irritates the eyes, nose, and sometimes skin. Standard operating procedures require double gloving, face shields, and well-fitted masks in the handling area. Safety Data Sheets spell out reaction exotherms and incompatibilities; I once witnessed a minor spill balloon into hours of containment when someone underestimated its volatility under light. Local exhaust and closed transfer systems protect workers and guarantee clean-up crews don’t face unforeseen hazard. Emergency kits nearby—eye wash stations, fire extinguishers—give peace of mind, underpinning factory culture built on safety.
This intermediate matters most for the pharmaceutical sector, but the broader picture reminds us why molecules like these deserve attention. Hospitals struggling against resistant Aspergillus or Candida rely on finished posaconazole, a safety net for immunosuppressed patients—bone marrow transplant recipients, organ transplant patients, or those with HIV/AIDS. I have seen patient outcomes link directly to supply chain resilience of intermediates; any hiccup in precursor synthesis can ripple out and mean drug shortages, leaving at-risk patients with fewer options. This intermediate’s robust, reliable supply ensures more people walk away from what used to be fatal fungal threats.
R&D teams keep busy pushing the boundaries of antifungal intermediates. Over the last decade, pharmaceutical companies have raced to refine reaction steps to cut waste or limit solvent use amid growing regulatory pressure. Green chemistry principles now shape many process improvements. Fully automated reaction monitoring, real-time spectroscopy, and digital twin plant modelling increasingly guide scale-up, rooting out sources of variability before they can threaten final drug quality. Universities join in, modeling and tweaking core triazole structures to seek even more potent derivatives that may one day leapfrog current drugs, often conducting shared studies across academia and industry.
Years working in drug safety taught me to double-check intermediate toxicity data as thoroughly as data on finished APIs. This intermediate, like many synthetic triazole precursors, carries toxicity risks mainly by inhalation or accidental ingestion. Animal studies and in vitro cytotoxicity screens determine safe handling thresholds. Chronic exposure investigation uses biomonitoring when scale ramps up; this goes beyond ticking regulatory boxes and aims to anticipate and minimize long-term risks for workers on the line every day. The goal: never let short-term commercial pressure override painstaking hazard evaluation.
Looking to what’s next, streamlined production and continuous process monitoring give the biggest returns in both efficiency and safety. Decades of incremental progress show up here—each improvement in yield, purity, or energy consumption counts, especially as global demand for antifungals climbs. Broader collaborations between generic manufacturers and research hospitals speed up tech transfer, aiming to keep life-saving drugs affordable and widely available. As synthetic biology tools mature, labs may one day craft this and similar intermediates right from engineered microorganisms, further slashing resource use and environmental footprint. Each push for better methods or smarter process control adds up, promising safer workplaces, steadier supply chains, and ultimately, better support for patients facing life-threatening fungal disease.
Posaconazole brings real benefit to patients who struggle with tough fungal infections, especially people whose immune systems do not fight like they should. The journey from chemical powders in a lab to life-saving antifungal medications does not happen overnight. Every effective medicine, like posaconazole, starts out as a series of complex building blocks known as intermediates. Posaconazole Intermediate 2 sits in the middle of this process. Chemists use it to construct the final active drug substance that ends up in hospitals and clinics.
Hospitals rely on antifungal drugs to pull people back from the edge during cancer treatment, organ transplants, and rare immune diseases. Fungi like Aspergillus can invade deep tissues in people with weakened defenses, making treatment options thin. Drugs like posaconazole are not easy to produce. The raw materials—these intermediates—must stay pure and precisely made, or the final drug may not work right or could become harmful. From my own experience talking to pharmacists and researchers, mistakes in the production pipeline can lead to medicine recalls or, even worse, treatments that fail just when patients need help the most.
Every intermediate, including Posaconazole Intermediate 2, asks for skilled hands and close attention in synthesis. Scientists work with specialized equipment to transform raw chemicals into the intermediate using controlled reactions. Each stage gets checked by strict quality controls. A single missed impurity can set back weeks of work. Without careful management at this stage, companies risk contaminating the final batches.
Drug shortages rarely make the news until a crisis breaks out. High quality intermediates let manufacturers keep up with worldwide demand for important medicines. Supply chain issues—maybe materials shipped late, maybe geopolitical tensions between countries—can slow access to these building blocks. I've seen how a small hiccup upstream can lead to price spikes and limited options for doctors and patients. Steady production of intermediates like Posaconazole Intermediate 2 helps to keep antifungal medications within reach for the people who need them most.
Any impurity or poorly made intermediate can compromise patient safety. Regulations require traceability down to the smallest chemicals used during drug development. Pharmaceutical executives talk about the challenge of following these rules without slowing innovation. Laboratories must prove that every batch of intermediate sticks to exact guidelines laid out by agencies like the FDA and EMA. Frequent audits and documentation provide a safety net, ensuring that only the safest and most effective drugs reach patients.
More investment in advanced manufacturing can reduce risks of human error and ramp up output. Digital tracking of chemical shipments helps spot problems before they halt production. Research partnerships between drug companies and universities may open new routes for making intermediates cheaper and safer. Advocating for policies that allow prompt sharing of technical knowledge can also dodge some of the delays now seen during public health emergencies.
Without reliable access to key intermediates like this, entire production lines for vital medicines could stall. By understanding what goes into creating posaconazole and its intermediates, communities and health professionals can push for stronger supply chains and smarter investments in drug development infrastructure.
Posaconazole sits on hospital shelves as a lifeline for those battling serious fungal infections. Before it gets that official label, years of lab work and chemical effort build the foundation. Early-stage molecules, often spoken about with names like “Posaconazole Intermediate 2,” drive that science forward. The formula for this vital step reads: C20H21Cl2F2N3O3. Chemists call it by its IUPAC name too: 4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-3-methylpiperazin-1-yl]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]-1,2-dichlorobutane.
Anyone working in pharma knows that the safety of the end product starts long before the medication forms a tablet. Sterile conditions crackle with tension as every lab tech and engineer controls for contaminants and impurities. A single impurity in an intermediate can ripple through the process, possibly evading the best analytical techniques. The wrong batch can mean lost confidence. Reputations in this industry take decades to build and only days to lose.
Several years back, I toured a mid-sized contract manufacturer as they scaled up a batch of Posaconazole Intermediates. The process shut down three times due to trace metals they traced back to a seemingly unrelated solvent drum. That memory sticks — lessons leaned toward rigorous quality checks at every step. No short cuts.
Intermediate structures rarely show up in public, cloaked by patents and cautious R&D secrecy. Developers invest years and millions into proprietary routes, guarding their methods almost like family recipes. The chemical structure C20H21Cl2F2N3O3 became public through patent filings, not press releases. This sort of transparency matters. When regulators or independent scientists access these details, safer generics get on the market quicker, costs drop, and patients see new options.
One challenge drags along with every proprietary molecule: balancing the drive for innovation with society’s need for affordable medicine. Those who have watched the flow of generics in emerging markets recognize battles in courtrooms over the technical language in a molecular formula. Somewhere along the way, clear communication between originator and generic makers supports the system—without it, bottlenecks hold up new drugs for everyone who waits.
Posaconazole Intermediate 2 needs tight analytical profiles. NMR, MS, HPLC—each test brings its own snapshot. Every chemist knows that knowing a chemical’s formula means little without reliable, reproducible means to confirm purity. I remember lab nights staring into HPLC output, waiting for the clean, expected peaks to roll in, sometimes hours after the midnight coffee. No analytical shortcuts save a product from recall.
Progress in pharmaceutical manufacturing rests on sharing solid information, following rigorous analytics, and protecting intellectual property in fair ways. As more data emerges about intermediates like Posaconazole Intermediate 2, expect safer drugs in more hands, available faster and at lower price points. Each new chemical formula shared, each batch tested without compromise, brings us one step closer to a world where advanced treatment doesn't depend on the size of a patient's wallet.
Dealing with pharmaceutical ingredients like Posaconazole Intermediate 2 means paying attention to every detail. Purity and grade aren’t just labels; they mean the difference between a batch that works and one that raises red flags in the lab or at the regulatory desk. Years spent alongside pharma developers has shown me that “close enough” risks more than an off-color solution—it risks patient outcomes.
In drug chemistry, grades and purity mark a kind of quality promise. Labs might request “research grade,” which could mean fewer controls, or “pharmaceutical grade,” which undergoes thorough checks for contaminants and meets standard specifications. Water content, residual solvents, and heavy metals content often get reported—each factor can make or break a synthesis or finished product. I’ve watched teams spend days deciphering certificates of analysis, hunting for the numbers that tell if a batch of Posaconazole Intermediate 2 can move forward.
Material suppliers in the pharmaceutical space work under tight guidelines. They understand that a slip—say, a small variation in impurity profile or process residue—can’t stay hidden. Audits, both scheduled and surprise, keep everyone sharpening their pencils and keeping their labs cleaner than most kitchens. If someone offers just one grade or skips out on test data, that raises a flag worth paying attention to.
Poor quality intermediates throw a wrench into testing, scaling, and most importantly, safety. One-off impurities have a way of becoming bad headlines or FDA 483s. I’ve seen batches sent back halfway across the world because a trace impurity slipped in at the intermediate stage.
Large producers in India and China sometimes advertise several “grades.” Product might be listable as “lab,” “GMP,” or “custom.” Labs or CMOs choosing these options have to check every data point—Globally Harmonized System labels, impurity thresholds, method of synthesis, and validation papers. Large clients never skip these steps. They know a small shortcut has a way of hitting the bottom line or delaying a crucial ANDA or NDA submission.
Trust in a supply chain isn’t just about contracts. It’s about getting batch-specific updates, detailed reports, and clear communication. The best suppliers welcome sample requests before big orders and respond openly to questions about their testing, scale-up capabilities, and batches retained for traceability.
In my own experience, a transparent supplier might offer side-by-side comparisons of grades, including COAs, impurity assays, process diagrams, and even visit invitations. They have nothing to hide, because their business grows by helping their clients meet regulatory and safety expectations.
Encouraging transparency fixes more than data gaps; it builds trust from bench chemist to production lead to regulator. Procurement decisions benefit from engaging scientists and quality professionals directly, so mistakes from mismatched specifications don’t creep in. Project leaders who invest time in understanding supplier capabilities and openly discuss regulatory risks protect their teams from surprise costs or missed launch dates.
Quality makes or breaks reputations, and in pharmaceuticals, that’s not an exaggeration. Any shortcut taken with the grade or purity of intermediates sets off a chain of risk that’s just not worth it.
Many people don’t spend much time thinking about what goes on behind the scenes to keep medicines safe and reliable. Posaconazole Intermediate 2 might sound technical, but it’s one of those compounds that demands respect. As someone who has seen both rushed production rooms and careful, buttoned-up labs, I’ve watched how a careless slip — a little extra light or a warm afternoon — can ruin a whole batch.
Chemicals of this kind don’t forgive mistakes. Official guidelines show it holds up best in tight conditions: cool air, low humidity, and darkness. Most storage rooms keep temperatures below 25°C (77°F) for a reason. Even a small rise opens the door to faster degradation, which chips away at stability and, in turn, can shake the foundation of later drug performance.
Moisture sneaks in quietly but unseals chemical bonds over time. Early in my career, I watched a critical batch left out during a thunderstorm. Doors flung open, water vapor slipped in. Sensors shot up. Within days, results swung wildly — from a stable powder to a sticky mess. Simple airtight containers don’t cut it. Manufacturers double down with sealed bags, secondary desiccants, and strict logbooks so every movement gets tracked.
Glass and amber bottles stand as protectors, shielding against both water and sunlight. Light exposure, especially sunlight or strong indoor lighting, accelerates breakdown processes. Hours of exposure can shrink a shelf life measured in months. Pharmacists learn fast to store it behind solid doors, away from any stray beams.
Many who work with pharmaceutical intermediates carry painful memories of mishaps. Gloves, goggles, and masks become standard issue not out of habit, but because a drop on bare skin or a breath of dust spells trouble. I’ve felt the sting of accidental contact and rushed for eyewash stations. The dust can get everywhere; slow, patient work pays off far more than speed.
Accurate labeling, tamper-evident seals, and batch records have their place. If anything feels off — a cracked seal, an unclear date, a faded label — the entire lot gets pulled aside for testing. The margin for error hovers near zero.
Labs try to avoid waste, but the risk of a contaminated batch reaching active pharmaceutical ingredient (API) status keeps everyone alert. Even slight impurities can cascade through the process, making treatments less reliable or, worse, dangerous.
Placing proper signage, training staff to spot early warning signs, and running regular storage audits keeps accidents in check. Automated monitoring systems flag high temperatures or humidity surges before people notice. Sometimes a quick move back to stable storage saves not just thousands of dollars, but future patients’ health down the line.
Trust in a medicine starts with a hundred small acts by the people who care for the compounds behind it. Looking after the details in storage and handling means fewer breakdowns, stable drugs, and fewer risks to the people counting on treatment.
Pharmaceutical manufacturing isn’t known for making life easy for buyers and sellers. When a company asks about sourcing large quantities of something as specialized as Posaconazole Intermediate 2, folks immediately check their supplier options. Take one look at the global API landscape. You’ll find a tangled mess of trade limitations, regulatory hurdles, and a constant push for stricter quality rules. Big players want to lock in reliable, safe, and cost-effective streams of intermediates, yet these ingredients don’t just flow in year-round like drinking water.
Antifungal drugs like posaconazole usually rank high in the hospital pharmacy. For anyone who has worked in clinical settings—or even stocked a research lab—the importance of robust supply lines jumps out fast. A glitch with intermediates can halt everything, resulting in lower access for patients. During the pandemic, interruptions with APIs not only caused delays but shot up final drug costs, pinching hospitals and driving patients to riskier alternatives.
Posaconazole suffers if one link snaps. Most suppliers focus on blockbuster molecules. Intermediates sometimes end up in the shadow, leaving procurement teams scrambling. Makers want dependable shipment schedules—monthly, quarterly, or annual—so they can keep production lines humming and avoid the painful rush of last-minute sourcing.
I’ve watched companies build new products but hit the wall trying to scale up. Without credible supply partners, even the best chemists twiddle their thumbs. Trust means more than just a one-off shipment. Buyers ask for batch-to-batch consistency, transparent documentation, and clear handling protocols. Mistakes here can set off an avalanche of headaches: compliance audits, production delays, and regulatory warnings.
No shortcut exists for good manufacturing practice. If a supplier cuts corners, it’s not just the buyer who pays the price. Patients see the impact. Regulatory bodies like the US FDA and EMA demand tight controls over solvents, trace elements, and sensitive impurities. Bad actors sometimes slip defective batches into the chain, causing notorious recalls and damaging reputations.
Real supply solutions come from producers who welcome audits, share certification logs, and work with third-party labs. Some API plants in India, China, and Europe carry that track record. Their managers employ skilled staff, test raw inputs, and modernize their processes long before the regulators show up.
From my experience dealing with custom synthesis, the smoothest partnerships come from those who open their books, not just their warehouses. Robust tech transfer protocols, constant customer communication, and long-standing worker skill form the backbone of trust. It takes more than competitive quotes. Mid-sized and big pharma scours the market each season, looking for reliability and transparency over the long haul, not just once.
Sourcing bulk quantities of intermediates like Posaconazole’s can work, but it demands teamwork, clarity, and shared responsibility. Customers and suppliers both shoulder the risk, but they also reap the reward: stronger health systems, cheaper medications, and a better shot at treating tomorrow’s tough infections.
| Names | |
| Preferred IUPAC name | 4-[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]-2-[(1S,2S)-1-ethyl-2-(1H-1,2,4-triazol-1-ylmethyl)butyl]-1,2,4-triazol-3-one |
| Other names |
4-[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxybenzonitrile Posaconazole Intermediate 2 |
| Pronunciation | /pəˌsækəˈnəʊzəl ɪn.təˈmiː.di.ət/ |
| Identifiers | |
| CAS Number | 170901-83-4 |
| Beilstein Reference | 127333-29-7 |
| ChEBI | CHEBI:144099 |
| ChEMBL | CHEMBL3981309 |
| ChemSpider | 2287691 |
| DrugBank | DB01263 |
| ECHA InfoCard | ECHA InfoCard: 100942-734-6 |
| EC Number | 1336272-13-1 |
| Gmelin Reference | 786262 |
| KEGG | C16685 |
| MeSH | D045169 |
| PubChem CID | 14050337 |
| RTECS number | VO2625000 |
| UNII | UD737375GF |
| UN number | UN3272 |
| CompTox Dashboard (EPA) | DTXSID10964796 |
| Properties | |
| Chemical formula | C23H32O4 |
| Molar mass | 414.47 g/mol |
| Appearance | White to off white solid |
| Odor | Odorless |
| Density | 1.3 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 3.8 |
| Acidity (pKa) | Acidity (pKa): "13.9 |
| Basicity (pKb) | 4.36 |
| Refractive index (nD) | 1.560 |
| Dipole moment | 4.05 D |
| Thermochemistry | |
| Std enthalpy of formation (ΔfH⦵298) | -282.4 kJ/mol |
| Pharmacology | |
| ATC code | J02AC04 |
| Hazards | |
| Main hazards | Causes serious eye damage. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | H317: May cause an allergic skin reaction. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P273, P280, P301+P312, P304+P340, P305+P351+P338, P312 |
| NFPA 704 (fire diamond) | 1-2-1-0 |
| Flash point | > 112.4°C |
| LD50 (median dose) | LD50 (median dose): >5000 mg/kg (rat, oral) |
| REL (Recommended) | 0.1 mg/m3 |
| Related compounds | |
| Related compounds |
Posaconazole Posaconazole Intermediate 1 Posaconazole Intermediate 3 Posaconazole N-oxide Posaconazole Impurity A |
